BioMarin Pharmaceutical Inc.
BMRN
$55.61
$0.180.33%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 18.36% | 19.36% | 17.97% | 19.14% | 15.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 18.36% | 19.36% | 17.97% | 19.14% | 15.83% |
| Cost of Revenue | 3.94% | 4.98% | 9.96% | -6.96% | -23.46% |
| Gross Profit | 26.18% | 27.66% | 22.56% | 40.63% | 60.56% |
| SG&A Expenses | -6.13% | 3.15% | 7.09% | 12.01% | 12.55% |
| Depreciation & Amortization | -59.08% | -44.43% | -30.47% | -22.02% | -5.35% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.18% | 0.33% | 4.16% | 10.04% | 10.56% |
| Operating Income | 223.09% | 233.45% | 183.99% | 143.42% | 104.47% |
| Income Before Tax | 181.25% | 184.09% | 187.31% | 158.08% | 176.29% |
| Income Tax Expenses | 334.30% | 371.57% | 449.31% | 1,385.08% | 418.73% |
| Earnings from Continuing Operations | 156.15% | 154.99% | 154.62% | 119.21% | 156.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 156.15% | 154.99% | 154.62% | 119.21% | 156.61% |
| EBIT | 223.09% | 233.45% | 183.99% | 143.42% | 104.47% |
| EBITDA | 151.38% | 148.79% | 115.05% | 86.12% | 60.12% |
| EPS Basic | 153.60% | 152.09% | 151.39% | 116.68% | 154.11% |
| Normalized Basic EPS | 206.55% | 216.36% | 186.84% | 123.24% | 96.60% |
| EPS Diluted | 158.99% | 157.25% | 157.15% | 117.91% | 156.99% |
| Normalized Diluted EPS | 211.46% | 217.41% | 184.32% | 120.67% | 94.99% |
| Average Basic Shares Outstanding | 1.10% | 1.15% | 1.17% | 1.21% | 1.26% |
| Average Diluted Shares Outstanding | 0.58% | 1.73% | 2.73% | 2.89% | 2.86% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |